Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 111
Filter
1.
J Am Coll Cardiol ; 38(5): 1416-23, 2001 Nov 01.
Article in English | MEDLINE | ID: mdl-11691517

ABSTRACT

OBJECTIVES: The objective of this study was to identify preprocedure patient factors associated with percutaneous intervention costs and to examine the impact of these patient factors on economic profiles of interventional cardiologists. BACKGROUND: There is increasing demand for information about comparative resource use patterns of interventional cardiologists. Economic provider profiles, however, often fail to account for patient characteristics. METHODS: Data were obtained from Duke Medical Center cost and clinical information systems for 1,949 procedures performed by 13 providers between July 1, 1997, and December 31, 1998. Patient factors that influenced cost were identified using multiple regression analysis. After assessing interprovider variation in unadjusted cost, mixed linear models were used to examine how much cost variability was associated with the provider when patient characteristics were taken into account. RESULTS: Total hospital costs averaged $15,643 (median, $13,809), $6,515 of which represented catheterization laboratory costs. Disease severity, acuity, comorbid illness and lesion type influenced total costs (R(2) = 38%), whereas catheterization costs were affected by lesion type and acuity (R(2) = 32%). Patient characteristics varied significantly among providers. Unadjusted total costs were weakly associated with provider, and this association disappeared after accounting for patient factors. The provider influence on catheterization costs persisted after adjusting for patient characteristics. Furthermore, the pattern of variation changed: the adjusted analysis identified three new outliers, and two providers lost their outlier status. Only one provider was consistently identified as an outlier in the unadjusted and adjusted analyses. CONCLUSIONS: Economic profiles of interventional cardiologists may be misleading if they do not adequately adjust for patient characteristics before procedure.


Subject(s)
Angioplasty, Balloon, Coronary/economics , Cardiac Catheterization/economics , Cardiology Service, Hospital/economics , Coronary Disease/diagnosis , Coronary Disease/economics , Data Interpretation, Statistical , Hospital Costs/statistics & numerical data , Models, Econometric , Practice Patterns, Physicians'/economics , Risk Adjustment , Academic Medical Centers , Aged , Angioplasty, Balloon, Coronary/statistics & numerical data , Bias , Cardiac Catheterization/statistics & numerical data , Comorbidity , Coronary Disease/physiopathology , Diagnosis-Related Groups/classification , Diagnosis-Related Groups/economics , Female , Health Services Research , Humans , Length of Stay/economics , Linear Models , Male , Middle Aged , North Carolina , Practice Patterns, Physicians'/statistics & numerical data , Retrospective Studies , Risk Factors , Severity of Illness Index , Stroke Volume
7.
AJR Am J Roentgenol ; 177(2): 309-16, 2001 Aug.
Article in English | MEDLINE | ID: mdl-11461851

ABSTRACT

OBJECTIVE: In September 1998, we began to treat iatrogenic femoral pseudoaneurysms with direct thrombin injection under sonographic guidance. Our purpose was to determine the success and complication rate of this technique. SUBJECTS AND METHODS: We treated 114 consecutive patients who had iatrogenic femoral pseudoaneurysms using direct thrombin injection. A 22-gauge spinal needle was placed into the pseudoaneurysm lumen with sonographic guidance, and bovine or human thrombin (mean dose, 306 U; range, 50--1600 U) was injected under continuous color Doppler sonographic visualization. Distal pulses were monitored. Patient demographics, clinical variables, and pseudoaneurysm characteristics were collected. RESULTS: One hundred three (90%) of 114 patients had pseudoaneurysm thrombosis after the first procedure. Of the remaining 11 patients who required a second procedure 1 day later, thrombosis occurred in seven (64%) of 11. Thus, the overall success rate was 96% (110/114). Of the patients who required one injection, the mean thrombosis time was 12 sec (range, 3--90 sec). Three (3%) of 114 patients required conscious sedation. Of the patients with successful thrombosis, 24-hr follow-up sonograms showed no recurrent pseudoaneurysm. Four patients (4%) had potential complications: a "blue toe" 15 hr after the thrombin injection that resolved spontaneously, a groin abscess, leg ischemia that resolved spontaneously after 4 hr, and crampy buttock pain that resolved spontaneously. CONCLUSION: For the treatment of iatrogenic femoral pseudoaneurysms, thrombin injection under sonographic guidance is a quick and effective method of therapy. Failures and complications are infrequent. At our institution, sonographically guided thrombin injection has replaced compression repair.


Subject(s)
Aneurysm, False/drug therapy , Femoral Artery , Hemostatics/therapeutic use , Iatrogenic Disease , Thrombin/therapeutic use , Ultrasonography, Interventional , Aged , Aneurysm, False/etiology , Animals , Cardiac Catheterization/adverse effects , Cattle , Female , Hemostatics/administration & dosage , Humans , Male , Thrombin/administration & dosage
8.
Am J Cardiol ; 88(3): 253-9, 2001 Aug 01.
Article in English | MEDLINE | ID: mdl-11472703

ABSTRACT

To compare the efficacy of self-expanding (SE) and balloon-expandable (BE) stents in native coronary arteries, we randomly assigned 1,096 patients with new and restenotic lesions to receive either device. Baseline demographics and coronary angiographic characteristics were similar in the 2 groups. The incidence of major adverse cardiac events including death, myocardial infarction, bypass surgery, and repeat intervention was similar for both groups at 1 month (2.9% vs 3.1% for SE vs BE, respectively) and at 9 months (19.3% vs 20.1%, SE vs BE respectively). In a subgroup of patients who underwent follow-up angiography (n = 250), the binary restenosis rates (24.2% vs 18.7%, p = 0.30), late loss (0.98 vs 94 mm, p = 0.60), and loss index (0.55 vs 55, p = 0.95) were not significantly different for both groups. In 62 patients who underwent intravascular ultrasound examination (IVUS), there was a trend toward a lower incidence of edge tears in the SE group (6% vs 23%, p = 0.06). Follow-up IVUS analysis showed that the minimum stent area of the SE stent increased by 33% at 6 months, whereas no change occurred in the BE stents; this was accompanied by a greater degree of intimal proliferation in the SE stents compared with BE stents (3.1 +/- 2.0 vs 1.7 +/- 1.7 mm(2)). Thus, the SE stents had similar clinical and angiographic outcomes in patients with lesions in native coronary arteries.


Subject(s)
Angioplasty, Balloon, Coronary , Coronary Disease/therapy , Stents , Coronary Disease/diagnostic imaging , Cross-Over Studies , Equipment Design , Female , Follow-Up Studies , Humans , Incidence , Male , Middle Aged , Myocardial Infarction/mortality , Pressure , Prospective Studies , Ultrasonography
9.
J Am Coll Cardiol ; 37(7): 1883-90, 2001 Jun 01.
Article in English | MEDLINE | ID: mdl-11401127

ABSTRACT

OBJECTIVES: To predict which patients might not require stent implantation, we identified clinical and angiographic characteristics associated with repeat revascularization after standard balloon angioplasty. BACKGROUND: Stents reduce the risk of repeat revascularization but are costly and may lead to in-stent restenosis, which remains difficult to treat. Identification of patients at low risk for repeat revascularization may allow clinicians to reserve stents for patients most likely to benefit. METHODS: Data from five interventional trials (5,146 patients) were pooled for analysis. We identified patients with optimal angiographic results (final diameter stenosis < or =30% and no dissection) after balloon angioplasty and determined the multivariable predictors of repeat revascularization. RESULTS: Optimal angiographic results were achieved in 18% of patients after angioplasty. The repeat revascularization rate at six months was lower for patients with optimal results (20% vs. 26%, p < 0.001) but still higher than observed in stent trials. Independent predictors of repeat revascularization were female gender (odds ratio [OR] 1.67, p = 0.01), lesion length > or =10 mm (OR 1.62, p = 0.03) and proximal left anterior descending coronary artery lesions (OR 1.62, p = 0.03). For the 8% of patients with optimal angiographic results and none of these risk factors, the repeat revascularization and target vessel revascularization rates were 14% and 8% respectively, similar to rates after stent implantation. Cost analysis estimated that $78 million per year might be saved in the U.S. with a provisional stenting strategy using these criteria compared with elective stenting. CONCLUSIONS: A combination of baseline characteristics and angiographic results can be used to identify a small group of patients at very low risk for repeat revascularization after balloon angioplasty. Provisional stenting for these low risk patients could substantially reduce costs without compromising clinical outcomes.


Subject(s)
Angioplasty, Balloon , Coronary Disease/therapy , Angioplasty, Balloon/economics , Coronary Disease/economics , Costs and Cost Analysis , Female , Humans , Male , Predictive Value of Tests , Stents
10.
Am J Ther ; 8(3): 155-62, 2001.
Article in English | MEDLINE | ID: mdl-11344383

ABSTRACT

Preexisting renal impairment is an all-encompassing risk factor for radiocontrast-associated nephrotoxicity. Renal impairment appears to be associated with the inadequate production of renal prostaglandins at the critical time of radiocontrast administration and for a variable time period afterward. We prospectively studied 130 patients with chronic renal insufficiency (serum creatinine > or =1.5 mg/dL) who were undergoing radiocontrast administration. Using a double-blind, randomized, prospective technique, patients were assigned to either placebo or one of three prostaglandin E1 (PGE1) treatment groups (10, 20, or 40 ng/kg/min). Infusion was started 60 +/- 30 minutes before the administration of radiocontrast and was continued for a total of 6 hours. In the placebo group, radiocontrast administration resulted in a mean increase (+/- SD) in serum creatinine of 0.72 +/- 1.15 mg/dL at 48 hours. This increase was less in each of the PGE1 treatment groups after 48 hours, with a significant difference between placebo and the 20 ng/kg/min PGE1 group (P = 0.01). Using baseline adjusted means, analysis of covariance with baseline serum creatinine as the covariable demonstrated significant differences between the placebo and 20 ng/kg/min PGE1 group (P = 0.03) and between the placebo and 10 ng/kg/min PGE1 group P = 0.047). In a subgroup analysis of the diabetic patients, the increase in serum creatinine was less pronounced in the three PGE1 groups versus the placebo group, and the 20 ng/kg/min PGE1 group had the most favorable outcome. The parenteral administration of PGE1 immediately before radiocontrast exposure and continued for a period of 5 to 5.5 hours significantly reduced the elevation of serum creatinine poststudy. The most effective of the three PGE1 dosing regimens was 20 ng/kg/min.


Subject(s)
Alprostadil/therapeutic use , Contrast Media/adverse effects , Creatinine/blood , Kidney Failure, Chronic/blood , Kidney/drug effects , Aged , Analysis of Variance , Double-Blind Method , Female , Humans , Kidney Failure, Chronic/complications , Male , Middle Aged , Pilot Projects , Prospective Studies
11.
Am Heart J ; 141(3): 469-77, 2001 Mar.
Article in English | MEDLINE | ID: mdl-11231447

ABSTRACT

BACKGROUND: Patients with prior coronary bypass surgery with acute ST-segment elevation myocardial infarction (MI) pose an increasingly common clinical problem. We assessed the characteristics and outcomes of such patients undergoing thrombolysis for acute MI. METHODS AND RESULTS: We compared the characteristics and outcomes of patients in the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries trial (GUSTO-I) who had had prior bypass (n = 1784, 4% of the population) with those without prior coronary artery bypass grafting (CABG), all of whom were randomized to receive one of four thrombolytic strategies. Patients with prior bypass were older with significantly more prior MI and angina. Overall, 30-day mortality was significantly higher in patients with prior bypass (10.7% vs 6.7% for no prior bypass, P <.001); these patients also had significantly more pulmonary edema, sustained hypotension, or cardiogenic shock. Patients with prior bypass showed a 12.5% relative reduction (95% confidence interval, 0% to 41.9%) in 30-day mortality with accelerated alteplase over the streptokinase monotherapies. In the 62% of patients with prior CABG who underwent coronary angiography, the infarct-related vessel was a native coronary artery in 61.9% and a bypass graft in 38.1% of cases. The Thrombolysis in Myocardial Infarction (TIMI) 3 flow rate was 30.5% for culprit native coronary arteries and 31.7% for culprit bypass grafts. Patients with prior bypass had more severe infarct-vessel stenoses (99% [90%, 100%] vs 90% [80%, 99%], P <.001). CONCLUSIONS: The 30-day mortality in patients with prior CABG was significantly higher than that for patients without prior CABG. As in the overall trial, these patients derived an incremental survival benefit from treatment with accelerated alteplase, but mortality remained high (16.7%) at 1 year. These results are at least partially explained by the higher baseline risk of these patients and by the lower rate of patency of the infarct-related artery.


Subject(s)
Coronary Artery Bypass , Myocardial Infarction/drug therapy , Thrombolytic Therapy , Coronary Angiography , Female , Fibrinolytic Agents/therapeutic use , Heparin/therapeutic use , Hospital Mortality , Humans , Male , Middle Aged , Postoperative Period , Randomized Controlled Trials as Topic , Streptokinase/therapeutic use , Thrombolytic Therapy/adverse effects , Tissue Plasminogen Activator/therapeutic use , Treatment Outcome
12.
Anesth Analg ; 92(4): 824-9, 2001 Apr.
Article in English | MEDLINE | ID: mdl-11273909

ABSTRACT

UNLABELLED: Apolipoprotein E (apoE) polymorphisms are heritable determinants of total and low-density lipoprotein cholesterol. The impact of apoE4 genotypes on the severity of atherosclerosis has been debated; however, recent studies have identified a correlation between apoE4 genotype and atherosclerosis. We assessed the impact of apoE4 genotype on age at first coronary artery bypass graft (CABG), hypothesizing that patients with the apoE4 allele are predisposed to coronary artery disease and present earlier for coronary revascularization. We assessed individual apoE genotypes and age in 560 patients undergoing primary CABG, by using analysis of variance (ANOVA) and controlling for gender. Because of the small number of patients in individual genotype groups, we compared patients with one or more copies of the apoE4 allele with those having no copies of the allele, again controlling for gender. A comparison of patients with one or more copies of the apoE4 allele with patients without the allele showed an earlier age at first CABG for those with the allele (P: = 0.032). Gene-dose analysis was also significant (P: = 0.012); patients with two copies of the allele presented at 54.2 +/- 6.9 yr. We report that the apoE4 allele is linked to age at first CABG. Identifying at-risk individuals may help prevent atherosclerosis. Further study is needed to define the mechanism of this association, and to define which coronary intervention is appropriate, based on long-term outcome. IMPLICATIONS: A correlation exists between apolipoprotein E (apoE) genotypes and the severity of atherosclerosis. We hypothesized that patients with the apoE4 allele are predisposed to coronary artery disease and present earlier for coronary artery bypass graft (CABG). Individuals with the apoE4 allele presented earlier for CABG, and the apoE4 allele is linked to age at first CABG.


Subject(s)
Apolipoproteins E/genetics , Coronary Artery Bypass , Polymorphism, Genetic/genetics , Age Factors , Aged , Alleles , Arteriosclerosis/genetics , Arteriosclerosis/surgery , Female , Genotype , Humans , Male , Middle Aged , Multivariate Analysis , Stroke Volume/physiology
13.
Am J Cardiol ; 87(4): 439-42, A4, 2001 Feb 15.
Article in English | MEDLINE | ID: mdl-11179529

ABSTRACT

Among 214 patients treated with abciximab within 24 hours of full-dose thrombolytic therapy, major bleeding occurred in 50 patients (23%; 95% confidence interval [CI] 18% to 30%) and intracranial hemorrhage occurred in 3 patients (1.4%; 95% CI 0.3% to 4%). The independent multivariate predictors of major bleeding were age (odds ratio [OR] 1.53/10 years, 95% CI 1.05 to 2.21, p = 0.03), time from thrombolytic to abciximab (OR 0.91/hour, 95% CI 0.83 to 0.99, p = 0.03), and intra-aortic balloon pump insertion (OR 4.42, 95% CI 2.00 to 9.72, p = 0.0002).


Subject(s)
Antibodies, Monoclonal/adverse effects , Hemorrhage/chemically induced , Immunoglobulin Fab Fragments/adverse effects , Platelet Aggregation Inhibitors/adverse effects , Abciximab , Aged , Angioplasty , Antibodies, Monoclonal/therapeutic use , Female , Fibrinolytic Agents/therapeutic use , Humans , Immunoglobulin Fab Fragments/therapeutic use , Logistic Models , Male , Middle Aged , Myocardial Infarction/complications , Myocardial Infarction/surgery , Myocardial Ischemia/etiology , Myocardial Ischemia/prevention & control , Platelet Aggregation Inhibitors/therapeutic use , Recombinant Proteins/therapeutic use , Risk Factors , Thrombolytic Therapy , Tissue Plasminogen Activator/therapeutic use , Treatment Failure
14.
Am J Cardiol ; 86(12): 1322-6, 2000 Dec 15.
Article in English | MEDLINE | ID: mdl-11113406

ABSTRACT

Despite the deleterious and sometimes catastrophic consequences of proximal left anterior descending (LAD) artery occlusion, there is a paucity of data to guide the treatment of patients with such disease. Our aim was to describe outcomes with medical therapy, angioplasty, or left internal mammary artery (LIMA) bypass grafting in patients with 1-vessel, proximal LAD disease. We retrospectively analyzed prospectively collected data from 1,188 patients first presenting only with proximal LAD disease at 1 center over 9 years. We assessed the rates of death, acute myocardial infarction, and repeat intervention by initial treatment over a median 5.7 years of follow-up. Patients undergoing angioplasty or LIMA bypass were more often men and had progressive or unstable angina; those receiving medical therapy had a lower median ejection fraction. Both revascularization procedures offered slightly better adjusted survival versus medicine (hazard ratio for angioplasty, 0.82; 95% confidence interval, 0.60 to 1.11; hazard ratio for bypass, 0.74; 95% confidence interval, 0.44 to 1.23). Bypass, but not angioplasty, was associated with significantly fewer composite end point events (death, infarction, or reintervention, p <0.0001), and angioplasty was associated with a higher composite event rate than bypass or medical therapy (p <0.0001 and p = 0.0003, respectively). The initial advantages of bypass and medicine over angioplasty diminished over time; angioplasty became more advantageous than medicine after 1 year (p = 0.05) and not significantly different from bypass. Treatment of 1-vessel, proximal LAD disease with medicine, angioplasty, or UMA bypass resulted in comparable adjusted survival. However, LIMA bypass alone reduced the long-term incidence of infarctions and repeat procedures.


Subject(s)
Angioplasty, Balloon, Coronary , Cardiovascular Agents/therapeutic use , Coronary Disease/therapy , Internal Mammary-Coronary Artery Anastomosis , Aged , Angina, Unstable/drug therapy , Angina, Unstable/surgery , Angina, Unstable/therapy , Cardiac Output, Low/etiology , Cohort Studies , Confidence Intervals , Coronary Disease/drug therapy , Coronary Disease/surgery , Disease Progression , Female , Follow-Up Studies , Humans , Incidence , Male , Middle Aged , Myocardial Infarction/etiology , Odds Ratio , Proportional Hazards Models , Prospective Studies , Reoperation , Retreatment , Retrospective Studies , Sex Factors , Stroke Volume , Survival Rate , Treatment Outcome
15.
Curr Interv Cardiol Rep ; 2(3): 258-266, 2000 08.
Article in English | MEDLINE | ID: mdl-11096675

ABSTRACT

Radiographic contrast agents have undergone a tremendous evolution over the past several decades. The creation of contrast agents with greater iodine carrying capacity and lower osmolality has improved imaging quality and reduced complications, including nausea, vomiting, congestive heart failure, and cardiac rhythm abnormalities. Whether differences exist among agents in terms of thrombotic complications remains controversial. Several characteristics including potential complications, toxicity, and cost must factor into the decision to use a particular contrast agent in cardiac procedures.

17.
J Am Coll Cardiol ; 36(4): 1142-51, 2000 Oct.
Article in English | MEDLINE | ID: mdl-11028463

ABSTRACT

Coronary stents reduce the rates of abrupt closure, emergency coronary artery bypass graft surgery and restenosis, but do not prevent myocardial infarction or death at six months. The financial burden of increased stent use and the difficulty in managing in-stent restenosis have provided the impetus to develop provisional stenting strategies. Patients at low risk for restenosis after balloon angioplasty may not derive additional benefit from stent implantation and may be successfully managed with percutaneous transluminal coronary angioplasty (PTCA) alone. Numerous patient, lesion and procedural predictors of restenosis have been identified. Postprocedural assessment using quantitative coronary angiography, intravascular ultrasound (IVUS), coronary flow velocity reserve (CVR) or fractional flow reserve (FFR) may further enhance the ability to predict adverse outcomes after PTCA. Several studies have been performed to investigate the feasibility of provisional stenting strategies using various modalities to identify low risk patients who could be managed with PTCA alone. An optimal or "stent-like" angiographic result after PTCA is associated with favorable clinical outcomes. Preliminary results of studies using IVUS or CVR to guide provisional stenting appear promising. Angiography alone may be inadequate to identify truly low risk patients and may need to be combined with clinical factors, assessment of recoil, IVUS or physiologic indexes. Strategies that avoid unnecessary stenting in even a small proportion of patients may have large impacts on health care costs. Provisional stenting may potentially reduce costs and rates of in-stent restenosis without compromising the quality of health care delivery.


Subject(s)
Blood Vessel Prosthesis Implantation , Coronary Disease/surgery , Decision Making , Stents , Coronary Angiography , Coronary Disease/diagnosis , Coronary Disease/economics , Graft Occlusion, Vascular/diagnosis , Graft Occlusion, Vascular/economics , Graft Occlusion, Vascular/prevention & control , Health Care Costs , Humans , Patient Selection , Prosthesis Design , Ultrasonography, Interventional
18.
Radiology ; 215(2): 403-8, 2000 May.
Article in English | MEDLINE | ID: mdl-10796916

ABSTRACT

PURPOSE: To evaluate and compare the treatment of iatrogenic femoral arterial pseudoaneurysms by using ultrasonographically (US) guided direct thrombin injection with US-guided compression repair. MATERIALS AND METHODS: Twenty-six patients with iatrogenic femoral arterial pseudoaneurysms were treated with direct thrombin injection. With US guidance, a 22-gauge needle was placed into the pseudoaneurysm flow lumen and thrombin (mean volume, 0.35 mL; range, 0.10-0.60 mL) was injected with continuous color Doppler US guidance. Demographics, clinical variables, pseudoaneurysm characteristics, and results in these patients were compared with those in 281 consecutive patients who underwent US-guided compression repair. RESULTS: The success rate of thrombin injection was 96% (25 of 26 patients), which was significantly higher than that of compression, 74% (209 of 281 patients) (P =.013). Twenty of 26 (77%) patients required a single injection, and six (23%) required two injections. Mean thrombosis time for thrombin injection was 6 seconds, compared with 41.5 minutes for compression. For thrombin injection, there were no complications, foot pulses did not change and no patients required conscious sedation. Follow-up US at 24 hours showed no recurrent pseudoaneurysms. CONCLUSION: For the treatment of iatrogenic femoral arterial pseudoaneurysms, thrombin injection with US guidance appears to be superior to compression repair.


Subject(s)
Aneurysm, False/drug therapy , Femoral Artery/injuries , Hemostatic Techniques , Hemostatics/administration & dosage , Iatrogenic Disease , Thrombin/administration & dosage , Ultrasonography, Interventional , Aged , Aneurysm, False/therapy , Chi-Square Distribution , Female , Follow-Up Studies , Foot/blood supply , Humans , Injections, Intra-Arterial , Injections, Intralesional , Male , Needles , Pressure , Pulse , Time Factors , Treatment Outcome , Ultrasonography, Doppler, Color
19.
Am J Cardiol ; 85(4): 435-40, 2000 Feb 15.
Article in English | MEDLINE | ID: mdl-10728946

ABSTRACT

Abciximab, an Fab monoclonal antibody fragment that blocks the platelet glycoprotein IIb/IIIa receptor, is increasingly used as an adjunct to coronary intervention. Little is known, however, about the efficacy and safety of readministration of abciximab. This study examined and characterized outcomes of patients receiving abciximab for a second time. From April 1995 to June 1997, 164 consecutive patients were readministered abciximab at our 3 institutions. We retrospectively examined and analyzed in-hospital outcomes in this cohort. The median time to readministration was 95 days. The angiographic success rate of percutaneous intervention was 99.5%. Rates and 95% confidence intervals of in-hospital events were death 2% (0.7% to 6.1%), myocardial infarction 3% (1% to 7%), coronary bypass surgery 0% (0% to 2.2%), and intracranial hemorrhage 2% (0.4% to 5.3%). Severe thrombocytopenia was observed in 4% of patients (1.4% to 7.8%) after readministration. Allergic or anaphylactic reactions were not observed. Major bleeding was associated with excessive concomitant antithrombotic therapy. Patients undergoing readministration of abciximab within 2 weeks of first administration experienced a higher incidence of severe thrombocytopenia (12% vs. 2%, p = 0.046). Thus, abciximab remains clinically efficacious when readministered as an adjunct to percutaneous coronary intervention. However, concomitant heparin administration must be carefully monitored and warfarin therapy should be avoided. Vigilant surveillance for thrombocytopenia should be employed. Reduced dosing may be necessary when abciximab is readministered within days of the initial administration.


Subject(s)
Antibodies, Monoclonal/administration & dosage , Coronary Disease/drug therapy , Immunoglobulin Fab Fragments/administration & dosage , Platelet Aggregation Inhibitors/administration & dosage , Abciximab , Aged , Antibodies, Monoclonal/adverse effects , Coronary Angiography , Coronary Disease/diagnostic imaging , Coronary Disease/surgery , Electrocardiography , Female , Humans , Immunoglobulin Fab Fragments/adverse effects , Injections, Intravenous , Intracranial Hemorrhages/chemically induced , Male , Middle Aged , Myocardial Revascularization , Platelet Aggregation Inhibitors/adverse effects , Platelet Glycoprotein GPIIb-IIIa Complex/antagonists & inhibitors , Postoperative Period , Retrospective Studies , Safety , Thrombocytopenia/chemically induced , Treatment Outcome
20.
Am J Cardiol ; 85(4): 446-50, 2000 Feb 15.
Article in English | MEDLINE | ID: mdl-10728948

ABSTRACT

Although coronary stenting has been shown to be effective, retrospective studies have suggested that stents do not provide better results than angioplasty in small coronary arteries. We sought to examine procedural, in-hospital, and long-term outcomes of patients undergoing small-vessel stenting with Palmaz-Schatz stents hand-crimped on a balloon catheter <3 mm in diameter. We retrospectively analyzed the outcomes of 117 patients who underwent this type of coronary stent implantation at Duke University Medical Center between January 1, 1997 and May 30, 1998. The clinical indications for percutaneous revascularization included unstable angina in 67.5% of patients, acute myocardial infarction in 4.3%, postinfarct angina in 3.4%, silent ischemia in 3.4%, and stable angina in 1% of patients. Quantitative angiographic analysis was performed immediately before angioplasty and after stent implantation. Stents were used for elective indications in 24%, for suboptimal angiographic result in 61.5%, and for abrupt and/or threatened closure in 14.5% of patients. Reference vessel diameter was similar before and after the procedure. Minimum luminal diameter increased from 0.63 to 2.35 mm, an acute gain of 1.72+/-0.43 mm. Percent stenosis decreased from 74.2% to 4.7%. The clinical composite of death (n = 1, 1%), nonfatal myocardial infarction (n = 6, 5.1%), and revascularization (n = 1, 1%) occurred in-hospital in only 8 patients (6.8%), resulting in clinical procedure success in 109 patients (93%). Our data suggest that stents designed for vessels >3.0 mm can be deployed in small vessels, with a low in-hospital event rate. However, target lesion revascularization in small vessels remains high. Development of antiproliferative strategies could improve long-term outcomes for small-vessel interventions.


Subject(s)
Blood Vessel Prosthesis Implantation , Coronary Disease/surgery , Coronary Vessels/surgery , Stents , Aged , Angioplasty, Balloon, Coronary , Cohort Studies , Coronary Angiography , Coronary Disease/diagnostic imaging , Coronary Disease/pathology , Coronary Vessels/pathology , Electrocardiography , Female , Hospital Mortality , Humans , Length of Stay , Male , Middle Aged , Retrospective Studies , Survival Rate , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL
...